• Andrew S Guinigundo, Cathy L Maxwell, Linda Vanni, Phuong Khanh Morrow, Maureen Reiner, Alex Shih, Zandra Klippel, and Elizabeth Blanchard.
• Oncology Hematology Care Inc., Cincinnati, Ohio.
• Pain Manag Nurs. 2018 Dec 1; 19 (6): 693-706.

BackgroundMild-to-moderate bone pain is the most commonly reported adverse event associated with pegfilgrastim.AimsTo investigate the effect of bone pain education on pegfilgrastim-related bone pain in patients with breast cancer receiving chemotherapy and pegfilgrastim.DesignRandomized, single-blind study.SettingsForty-eight community oncology clinics throughout the United States.ParticipantsThree hundred women ≥18 years of age with newly diagnosed stage I -III breast cancer, who were planning ≥4 cycles of neoadjuvant or adjuvant chemotherapy with pegfilgrastim support starting in cycle 1.MethodsPatients were randomized 1:1 to view a general education DVD on chemotherapy side effects (GE-DVD) or a DVD on bone pain following chemotherapy and pegfilgrastim (BP-DVD). Patients recorded severity of bone pain on a scale of 0-10, location of pain, and use of bone pain medications (i.e., analgesics, antihistamines, and nonsteroidal anti-inflammatory drugs) for 5 days, beginning on the day of pegfilgrastim administration, in each of the first four chemotherapy cycles.ResultsPatient-reported maximum bone pain was similar in the two groups (GE-DVD vs BP-DVD: cycle 1, 3.2 vs. 3.5, p = .3479; across all cycles, 4.1 vs. 4.6, p = .2196). Other measures of bone pain were also similar between the groups. Bone pain was highest in cycle 1 but decreased and then remained stable in subsequent cycles. Bone pain medication use was similar in both groups and was highest in cycle 1.ConclusionsThe bone pain-specific education evaluated here did not improve perceptions of bone pain reported in this patient population.Copyright © 2018 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights reserved.

34 keywords...

hide…